The FDA is proposing a new rule that would require agency approval prior to the implementation of any LDT. Some proponents believe this approval could have prevented Theranos's deception with its diagnostic claims.
A Harvard Medical School psychiatrist warns that the FDA's proposed rule may lead to more harm than good, suggesting a more intensive validation program for LDTs instead.
[
add
]
[
|
|
...
]